Dr. Dan Zhang was interviewed by PharmaAsia news on the new drug safety regulation issued by SFDA.
2009-9-22
"The new version has expanded significantly ¡­ It clearly spells out the reporting timeline for death case, as well as AE and SAEs. It also clearly identifies the role/responsibilities of city level, provincial level and SFDA in handling AE and SAE cases. "For detail information on the new regulation and its impact on conducting clinical trials in China. Please contact FMD for one-on-one consultation.
Latest News
Fountain will exhibit at both ASCO and DIA Annual Meetings next month

Come see us at ASCO, Chicago, USA, June 5 to 7, 2010, Booth # 2011
Come see us at DIA, Washington DC, USA, June 14 to 16, 2010,Booth # 1905
Fountain will exhibit at both ASCO and DIA Annual Meetings next month. Principals from our China offices are excited to be there to answer any questions you have about what has become the new frontier in drug development.

A grateful letter from CDE

“It is a great honor that our president & CEO Dr Zhang Dan has been invited as consultant by CDE. Per invitation he gave an important presentation in CDE seminar of innovative drug R & D, Shanghai 2009. Hereby CDE express high appreciation of his work with the thanking letter. ”

USA
Joanne Jiang, Ph.D., MBA
Fountain Medical Development
Tel: 732-447-6898
Email:joanne.jiang@fountain-med.com
BEIJING(China)
Phone: 86-10-8440-6940
SHANGHAI(China)
Phone:86-21-51088628
TIANJIN(China)
Phone: 86-22-25327420
Welcome to FMD